Silver Book Fact

Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.

Innovation in the Biopharmaceutical Pipeline: A multidimensional view. http://www.phrma.org/sites/default/files/pdf/2013innovationinthebiopharmaceuticalpipeline-analysisgroupfinal.pdf. Published 2013

Reference

Title
Innovation in the Biopharmaceutical Pipeline: A multidimensional view.
Publisher
Analysis Group
Publication Date
Published 2013
Authors
Long, G and J Works
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Improvement in 5-Year Survival Rates for All Cancers Since 1975
     
  • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
  • Widespread use of telomerase inhibitors could result in a 50% cure rate and a 25% prolongation of life for 50% of eligible patients with solid tumors.  
  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.  
  • Investments in cancer research and development between 1998 and 2000 has generated 23 million additional healthy years of life and $1.9 trillion of additional social value.